Latest news

• NICE set to back Parsabiv for kidney disease complication

  In draft guidance, the cost-effectiveness agency is backing use of Amgen's Parsabiv (etelcalcetide) for secondary hyperparathyroidism caused by CKD in patients on haemodialysis, but only for patients who cannot ... Parsabiv was approved by the EMA last

• Amgen's chronic kidney disease drug Parsabiv cleared in US

  Amgen has finally been granted FDA approval for its Parsabiv therapy for a complication of chronic kidney disease (CKD), after being turned down by the US regulator last summer. ... to be used in clinical practice, the monthly costs of Parsabiv and

• Amgen wins European approval for Parsabiv

  European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... In contrast, Parsabiv is administered as an infusion during

• FDA knocks back Amgen's chronic kidney disease treatment

  Parsabiv was hoped to equal or exceed solid earner Sensipar. Amgen has been dealt a blow to its late-stage pipeline by the FDA, which has declined to approve a ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping the